[1]何佳玲 陈应忠 刘浩然 叶滔 谢轲 徐俊波 刘汉雄 蔡琳.预防性静脉-动脉体外膜肺氧合支持下的经导管主动脉瓣植入术[J].心血管病学进展,2022,(2):113.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.005]
 HE JialingCHEN YingzhongLIU HaoranYE TaoXIE KeXU Junbo,LIU HanxiongCAI Lin.Prophylactic Venous-Arterial Extracorporeal Membrane Oxygenation Supported Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2022,(2):113.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.005]
点击复制

预防性静脉-动脉体外膜肺氧合支持下的经导管主动脉瓣植入术()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2022年2期
页码:
113
栏目:
综述
出版日期:
2022-02-25

文章信息/Info

Title:
Prophylactic Venous-Arterial Extracorporeal Membrane Oxygenation Supported Transcatheter Aortic Valve Implantation
作者:
何佳玲1 陈应忠1 刘浩然1 叶滔1 谢轲2 徐俊波1 刘汉雄1 蔡琳1
(1. 西南交通大学附属医院 成都市第三人民医院心内科,四川 成都 610031;2. 西南交通大学附属医院 成都市第三人民医院重症医学科,四川 成都 610031)
Author(s):
HE Jialing1CHEN Yingzhong1LIU Haoran1YE Tao1XIE Ke2XU Junbo2LIU Hanxiong1CAI Lin1
(1. Department of Cardiology,The Third People’s Hospital of Chengdu,The Affiliated Hospital of Southwest Jiaotong University,Chengdu 610031,Sichuan,China;2. Department of Intensive Care Unite,The Third People’s Hospital of Chengdu,The Affiliated Hospital of Southwest Jiaotong University,Chengdu 610031,Sichuan,China)
关键词:
预防性静脉-动脉体外膜肺氧合经导管主动脉瓣植入术左室射血分数
Keywords:
Prophylactic veno-arterial extracorporeal membrane oxygenationTranscatheter aortic valve implantationLeft ventricular ejection fraction
DOI:
10.16806/j.cnki.issn.1004-3934.2022.02.005
摘要:
经导管主动脉瓣植入术是治疗重度主动脉瓣狭窄的有效方法,当遇到诸如低射血分数的极高危患者,可能需要静脉-动脉体外膜肺氧合这样的机械设备的辅助治疗。现通过介绍1例成功在预防性静脉-动脉体外膜肺氧合应用下进行经导管主动脉瓣植入术的高危、低射血分数患者,进一步讨论当前国内外静脉-动脉体外膜肺氧合在经导管主动脉瓣植入术中的应用情况以及存在的问题。
Abstract:
Transcatheter aortic valve implantation(TAVI) is an efficient treatment of severe aortic valve stenosis. When we encounter extremely high risk patient like very low ejection fraction ,we may need mechanical support among which venous-arterial extracorporeal membrane oxygenation(VA-ECMO) is a common and effective one. This article report a TAVI case which was advanced in years,with very low ejection fraction and varies complications supported under prophylatic VA-ECMO. This patient was successfully operated and leave hospital with remarkably improved ejection fraction. Eventually we reviewed VA-ECMO especially prophylactic VA-ECMO implication in TAVI therapy at present and the existing problems.

参考文献/References:


[1] Morís C,Pascual I,Avanzas P. Will TAVI be the standard of care in the treatment of aortic stenosis?[J]. Rev Esp Cardiol(Engl Ed) ,2016,69(12):1131-1134.

[2] Otto CM,Nishimura RA,Bonow RO,et al. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice Guidelines[J]. Am J Cardiol,2021,77(4):450-500.

[3] Reardon MJ,van Mieghem NM,Popma JJ,et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients[J]. N Engl J Med,2017,376(14):1321-1331.

[4] Leon MB,Smith CR,Mack MJ,et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients[J]. N Engl J Med,2016,374(17):1609-1620.

[5] Baumgartner H,Falk V,Bax JJ,et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease[J].Eur Heart J,2017,38(36):2739-2791.

[6] Singh V,Patel SV,Savani C,et al. Mechanical circulatory support devices and transcatheter aortic valve implantation (from the National Inpatient Sample) [J]. Am J Cardiol,2015,116(10):1574-1580.

[7] Windecker S,Kolh P,Alfonso F,et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI)[J]. Eur Heart J,2014,35(37):2541-2619.

[8] Trenkwalder T,Pellegrini C,Holzamer A,et al. Emergency extracorporeal membrane oxygenation in transcatheter aortic valve implantation: a two-center experience of incidence,outcome and temporal trends from 2010 to 2015 [J]. Catheter Cardiovasc Interv,2018,92(1):149-156.

[9] Drews T,Pasic M,Buz S,et al. Elective femoro-femoral cardiopulmonary bypass during transcatheter aortic valve implantation: a useful tool[J]. J Thorac Cardiovasc Surg,2013,145(3):757-763.

[10] Neumann FJ,Sousa-Uva M,Ahlsson A,et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. The task force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery(EACTS)[J]. G Ital Cardiol(Rome),2019,20(7-8 Suppl 1):1S-61S.

[11] Yancy CW,Jessup M,Bozkurt B,et al. 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2013,62(16):e147-e239.

[12] Husser O,Holzamer A,Philipp A,et al. Emergency and prophylactic use of miniaturized veno-arterial extracorporeal membrane oxygenation in transcatheter aortic valve implantation[J]. Catheter Cardiovasc Interv,2013,82(4):E542-E551.

[13] Uehara K,Minakata K,Saito N,et al. Use of extracorporeal membrane oxygenation in complicated transcatheter aortic valve replacement[J]. Gen Thorac Cardiovasc Surg,2017,65(6):329-336.

[14] Raffa GM,Kowalewski M,Meani P,et al. In-hospital outcomes after emergency or prophylactic veno-arterial extracorporeal membrane oxygenation during transcatheter aortic valve implantation:a comprehensive review of the literature[J]. Perfusion,2019,34(5):354-363.

[15] Trenkwalder T,Pellegrini C,Holzamer A,et al. Prophylactic ECMO during TAVI in patients with depressed left ventricular ejection fraction[J]. Clin Res Cardiol,2019,108(4):366-374.

[16] Seco M,Forrest P,Jackson SA,et al. Extracorporeal membrane oxygenation for very high-risk transcatheter aortic valve implantation[J]. Heart Lung Circ,2014,23(10):957-962.

[17] 杨博,徐嗣卫,郦安琪,等. 经导管主动脉瓣置换术后体外膜肺氧合转Impella长时间辅助一例[J]. 中华急诊医学杂志,2021,30(3):365-367.

[18] Hu P,Liu XB,Liang J,et al. A hospital-based survey of patients with severe valvular heart disease in China[J]. Int J Cardiol,2017,231:244-247.

[19] Pan W,Zhou D,Cheng L,et al. Candidates for transcatheter aortic valve implantation may be fewer in China[J]. Int J Cardiol,2013,168(5):e133-e134.

[20] 《中国心血管健康与疾病报告2019》编写组. 《中国心血管健康与疾病报告2019》要点解读[J]. 中国心血管杂志,2020,25(5):401-410.

[21] Mack MJ,Leon MB,Thourani VH,et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients[J]. N Engl J Med,2019,380(18):1695-1705.

[22] Muller Moran HR,Eikelboom R,Lodewyks C,et al. Two-year outcomes from the PARTNER 3 trial:where do we stand?[J].Curr Opin Cardiol,2021,36(2):141-147.

[23] Popma JJ,Deeb GM,Yakubov SJ,et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients[J]. N Engl J Med,2019,380(18):1706-1715.

[24] 周达新,潘文志,吴永健,等. 经导管主动脉瓣置换术中国专家共识(2020更新版)[J]. 中国介入心脏病学杂志,2020,28(6):301-309.

[25] 中国心胸血管麻醉学会,中华医学会麻醉学分会,中国医师协会麻醉学医师分会,等. 不同情况下成人体外膜肺氧合临床应用专家共识(2020版)[J]. 中国循环杂志,2020,35(11):1052-1063.

相似文献/References:

[1]王慧,饶莉.经导管主动脉瓣植入术的影像学研究进展[J].心血管病学进展,2015,(5):531.[doi:10.3969/j.issn.1004-3934.2015.05.002]
 WANG Hui,RAO Li.Advances in Study of Imaging of Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2015,(2):531.[doi:10.3969/j.issn.1004-3934.2015.05.002]
[2]蒲华霞 彭礼清.多层螺旋CT在经导管主动脉瓣植入术前评估中的研究进展[J].心血管病学进展,2019,(9):1278.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.024]
 PU HuaxiaPeng Liqing.Preoperative Evaluation of Transcatheter Aortic Valve Implantation with Multi-detector Computed Tomography[J].Advances in Cardiovascular Diseases,2019,(2):1278.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.024]
[3]张文博 谢进生.经导管主动脉瓣中瓣植入术的并发症及其处理进展[J].心血管病学进展,2021,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
 ZHANG Wenbo,XIE Jinsheng.Complications and Management of Valve-in-valve Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2021,(2):1.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[4]董一娜 雷芳芳 宋启煦 王晶 杨艳.经导管主动脉瓣置换术后死亡风险预测模型系统评价[J].心血管病学进展,2022,(1):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
 DONG Yina,LEI Fangfang,SONG Qixu,et al.Mortality Risk Prediction Models After Transcatheter?span>Aortic Valve Replacement:A Systematic Review[J].Advances in Cardiovascular Diseases,2022,(2):76.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.020]
[5]王璐 李耀东.TAVR合并心房颤动抗凝策略的研究进展[J].心血管病学进展,2022,(8):695.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.007]
 WANG Lu,LI Yaodong.Anticoagulation Strategy in Patients After TAVR Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(2):695.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.007]
[6]周浩 兰富霞 徐英.经导管主动脉瓣植入术后发生脑血管事件的研究进展[J].心血管病学进展,2023,(11):965.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.002]
 ZHOU Hao,LAN Fuxia,XU Ying.Cerebrovascular Events After Transcatheter Aortic Valve Implantation[J].Advances in Cardiovascular Diseases,2023,(2):965.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.002]

更新日期/Last Update: 2022-08-19